Form 4: Teladoc Health Director Kenneth Paulus Granted Over 28,000 Restricted Stock Units

Teladoc Health, Inc. Director Kenneth H. Paulus was granted 28,986 restricted stock units (RSUs) on May 22, 2025, as part of his compensation.

Summary

• Kenneth H. Paulus, a Director of Teladoc Health, Inc. (TDOC), was granted 28,986 Restricted Stock Units (RSUs) on May 22, 2025.
• Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
• The RSUs were acquired at a price of $0, which is typical for compensation grants.
• The restricted stock units are scheduled to vest in full on the earlier of May 22, 2026, or the day immediately preceding the issuer's 2026 annual meeting of stockholders.
• Vested shares will be delivered to Mr. Paulus on the earliest to occur of (i) within 90 days following the date that is 30 days following his separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors), and (iii) his death.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard compensation practice that aligns director interests with shareholders. It is a routine event and not a significant catalyst for stock price movement.

Positives

• The grant of restricted stock units to a director aligns their interests with those of shareholders, as the value of the compensation is directly tied to the company's stock performance.
• This compensation indicates the company's ongoing commitment to retaining and incentivizing key board members.

Risks

• The ultimate value of the granted RSUs to the director is contingent on the future market price of Teladoc Health's common stock; a decline in stock price would reduce the value of this compensation.
• The vesting conditions require the director to remain with the company until the specified vesting date to fully realize the value of the grant.

Future Outlook

This filing primarily details an insider compensation event and does not provide a general future outlook or financial guidance for Teladoc Health, Inc. However, it implies continued alignment of a director's incentives with the company's long-term stock performance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of equity compensation to a director. Such grants are a common practice across various industries, including healthcare technology, to attract, retain, and incentivize board members by aligning their financial interests with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of director compensation is a widely adopted practice across publicly traded companies, including those in the healthcare technology sector.
• The specific number of units granted (28,986) and the vesting schedule (full vesting on the earlier of a specific date or the next annual meeting) are typically determined by the company's compensation committee based on peer group analysis and market benchmarks for director compensation. Without access to Teladoc Health's specific compensation policies or peer group data, a direct quantitative comparison to specific comparable companies or projects is not feasible from this document alone.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value. It also represents a minor potential for future share dilution upon vesting.

Next Steps

• The granted Restricted Stock Units will vest on the earlier of May 22, 2026, or the day immediately preceding Teladoc Health's 2026 annual meeting of stockholders.
• Vested shares will be delivered to the reporting person upon separation of service, a Change of Control, or the reporting person's death.

Key Dates

Keywords

Teladoc Health, TDOC, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Kenneth Paulus